{"id":"W2947381343","doi":"10.1200/jco.2019.37.15_suppl.1041","title":"Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2– advanced breast cancer (ABC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Discontinuation; Internal medicine; Population; Letrozole; Breast cancer; Interim analysis; Hazard ratio; Cancer; Chemotherapy regimen; Adverse effect; Oncology; Confidence interval; Clinical trial; Tamoxifen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006661045,0.001207109,0.001294766,0.0004042155,0.0005842093,0.001456894,0.0005663888,0.001000273,0.00969157],"category_scores_gemma":[0.003946348,0.0003858117,0.00161267,0.0004882028,0.0003737352,0.000977234,0.0005780626,0.002092722,0.001769885],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006909733,"about_ca_system_score_gemma":0.001467648,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005197708,"about_ca_topic_score_gemma":0.001559369,"domain_scores_codex":[0.9987009,0.00068499,0.00008963948,0.0001321553,0.0001935343,0.0001986869],"domain_scores_gemma":[0.9974475,0.0008238631,0.0006062799,0.0002953361,0.0002521905,0.0005748943],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7080425,0.01216785,0.03533198,0.001563647,0.005287358,0.0007571829,0.0003245533,0.005121688,0.02350692,0.0008154427,0.06731293,0.1397678],"study_design_scores_gemma":[0.3501495,0.3406274,0.2000026,0.0002817171,0.008400679,0.00225445,0.0001998001,0.003960392,0.01629149,0.002052802,0.07564171,0.0001373154],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8563355,0.009008634,0.005856403,0.00277735,0.0005982395,0.01089619,0.08316312,0.0007560142,0.03060861],"genre_scores_gemma":[0.864314,0.002166742,0.007777308,0.003334278,0.000423389,0.01083964,0.09850042,0.0001983902,0.01244578],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00969157,"threshold_uncertainty_score":0.03522736,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1299282133590225,"score_gpt":0.5039471352598323,"score_spread":0.3740189219008098,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}